ERBB2 and neoplasm: It has demonstrated promising anti-tumor activity in pre-clinical and early clinical studies (phase II, single arm, n-43), showing ORR of 51.2% (35.5–66.7%) as a second line treatment of patients with HER2+ locally advanced or metastatic urothelial cancer previously treated platinum-containing chemotherapy.